The Regulatory Fast Lane: How the FDA's Streamlined Pathways Are Unlocking In Vivo Gene Editing

• The Problem: Gene editing therapies face a regulatory paradox — the diseases they target are so rare that traditional two-trial approval standards are practically impossible to meet.

• The Signal: The FDA’s February 2026 “Plausible Mechanism Framework” draft guidance allows approval on a single well-controlled study with confirmatory evidence, specifically prioritising genome editing therapies.

• The Opportunity: The gene therapy market is compounding at ~19.8% annually toward $77.6 billion by 2035, and the regulatory bottleneck just got significantly narrower.

• The Thesis: Beam Therapeutics (BEAM) is the clearest near-term beneficiary with a BLA filing expected by year-end 2026. Prime Medicine (PRME) is the micro-cap speculative play — first-ever human prime editing data showed results that stunned the field, and the stock is trading at $2.98 with a $538M market cap.

Here is the thing about rare genetic diseases: they are not rare to the people w…

Continue reading this post for free, courtesy of Solar Kitties Alt Investments.